News >

Novel Agents, Genetic Testing Propel Personalized Care in Ovarian Cancer

Angelica Welch
Published: Tuesday, Aug 28, 2018

Angeles Alvarez Secord, MD

Angeles Alvarez Secord, MD

Treatment for patients with ovarian cancer has evolved considerably over the last few years, in part due to the implementation of genetic testing.

State of the Science Summit™ on Ovarian Cancer, Secord, a gynecologic cancers specialist at Duke Cancer Center, discussed recent updates in ovarian cancer, with an emphasis on the clinical significance of genetic testing.

OncLive: Reflecting on the different presentations tonight, what does this signify about the progress being made in this disease?

Secord: We have made incredible progress in ovarian cancer. Some of this program provided basics in terms of the landscape and the treatment of women with newly diagnosed disease, as well as surgical management of ovarian cancer. The first half of the meeting dealt with how to treat someone with advanced, newly diagnosed ovarian, fallopian tube, and peritoneal cancer. We covered the chemotherapy options, as well as the surgical management. Importantly, we also discussed genetic testing. This part of the program provided a hint of what is to come. That is personalized medicine—individualized care for women who have these types of cancers.

Additionally, genetic testing can identify women who are at an increased risk for breast and ovarian cancer, so we can use this information to prevent other cancers. That is so striking to me—the fact that we can identify women who have a genetic predisposition to ovarian and breast cancer. Now, it is even beyond that; we are able to identify increased risk of pancreatic and other cancers. We can institute cancer screening, give treatments to try to prevent these cancers, or even surgery. We will be able to reduce ovarian, fallopian tube, and peritoneal cancer incidence by about 20%.

In regard to genetic testing, how do you choose when and how to test these patients?

As soon as someone has a diagnosis of ovarian, fallopian tube, or peritoneal cancer, I am talking to them about genetic testing. We have a fantastic program at Duke Cancer Institute, and we are very fortunate to have a genetic center that is available to us. The genetic counselors will [guide] patients regarding the different tests available, the importance of testing, and the different outcomes of the tests. For instance, they may have a test that indicates a pathologic mutation that puts [the patient] at an increased risk. Or, they could have a test that is negative. However, in the setting of significant family history, they are still at an increased risk.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication